Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oxymorphone ER in Cancer or Neuropathic Pain
NCT00911261Phase 3Completed
- Sponsor
- Endo International plc
- Start
- Aug 2003
- Primary completion
- Mar 2005
- Modality
- Small Molecules
01
Overview
Phase 3, open-label, single-arm trial of oxymorphone in chronic pain, neuropathic pain and cancer pain, sponsored by Endo International plc. Primary endpoint: Tolerability at 12 months. Started Aug 2003; status: completed.
02
Drugs
oxymorphone
03
Conditions
chronic painneuropathic paincancer pain
Beyond the preview
Go deeper on NCT00911261.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00911261.